OC-0609: The PET-boost trial: isotoxic homogeneous or FDG-directed dose escalation in stage II-III NSCLC. (November 2020) - Cooke, S.; De Ruysscher, D.; Reymen, B.; Lambrecht, M.; Persson, G. Fredberg; Faivre-Finn, C.; Dieleman, E.; Lewensohn, R.; Van Diessen, J.; Sikorska, K.; Lalezari, F.; Sonke, J.; et al.